Journal Article

Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma

Gerloff, Dennis, Gebhardt, Kathleen, Sunderkötter, Cord, Uebel, Anne, Willscher, Edith, Kewitz-Hempel, Stefanie

2023

Overview

Activating BRAF mutations occurs in 50–60% of malignant melanomas. Although initially treatable, the development of resistance to BRAF-targeted therapies (BRAFi) is a major challenge and limits their efficacy. We have previously shown that the BRAFV600E signaling pathway mediates the expression of EZH2, an epigenetic regulator related to melanoma progression and worse overall survival. Therefore, we wondered whether inhibition of EZH2 would be a way to overcome resistance to vemurafenib. We found that the addition of an EZH2 inhibitor to vemurafenib improved the response of melanoma cells resistant to BRAFi with regard to decreased viability, cell-cycle arrest and increased apoptosis. By next-generation sequencing, we revealed that the combined inhibition of BRAF and EZH2 dramatically suppresses pathways of mitosis and cell cycle. This effect was linked to the downregulation of Polo-kinase 1 (PLK1), a key regulator of cell cycle and proliferation. Subsequently, when we inhibited PLK1, we found decreased cell viability of melanoma cells resistant to BRAFi. When we inhibited both BRAF and PLK1, we achieved an improved response of BRAFi-resistant melanoma cells, which was comparable to the combined inhibition of BRAF and EZH2. These results thus reveal that targeting EZH2 or its downstream targets, such as PLK1, in combination with BRAF inhibitors are potential novel therapeutic options in melanomas with BRAF mutations.

• Publisher: MDPI AG,MDPI
• Subject: Apoptosis / Cell cycle / Cell growth / Cell Line, Tumor / Drug Resistance, Neoplasm - genetics / Enhancer of Zeste Homolog 2 Protein - genetics / Enhancer of Zeste Homolog 2 Protein - metabolism / Epigenetics / Gene expression / Humans / Indoles - pharmacology / Indoles - therapeutic use / Medical prognosis / Melanoma / Melanoma - drug therapy / Melanoma - genetics / Melanoma - pathology / Metastasis / Mutation / Phosphorylation / Polo-Like Kinase 1 / Protein Kinase Inhibitors - pharmacology / Protein Kinase Inhibitors - therapeutic use / Proto-Oncogene Proteins B-raf - genetics / Proto-Oncogene Proteins B-raf - metabolism / Skin cancer / Skin Neoplasms - drug therapy / Skin Neoplasms - genetics / Skin Neoplasms - pathology / Sulfonamides - pharmacology / Sulfonamides - therapeutic use / Tumors / Vemurafenib - pharmacology / Vemurafenib - therapeutic use